A Phase III Study (CheckMate 238) of Adjuvant Immunotherapy With Nivolumab (NIVO) Versus Ipilimumab (IPI) After Complete Resection of Stage IIIb/c or Stage IV Melanoma (MEL) in Patients (Pts) at High Risk for Recurrence

Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1186/2051-1426-3-s2-p166
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Cost-Effectiveness of Nivolumab (NIVO) Combined With Ipilimumab (IPI) Compared With Nivo and Ipi Monotherapies in the First-Line Treatment of Advanced Melanoma in the United States: Analysis Using 28-Month Overall Survival (OS) Data From Checkmate 067

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Fatal Myocarditis and Rhabdomyositis in a Patient With Stage IV Melanoma Treated With Combined Ipilimumab and Nivolumab

Current Oncology
Oncology
2019English

P2.16-03 CheckMate 816: A Phase 3 Trial of Neoadjuvant Nivolumab Plus Ipilimumab or Chemotherapy vs Chemotherapy in Early-Stage NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Q-TWiST Analysis Comparing Ipilimumab/Dacarbazine vs Placebo/Dacarbazine for Patients With Stage III/IV Melanoma

British Journal of Cancer
Cancer ResearchOncology
2013English

Adjuvant Ipilimumab in High-Risk Uveal Melanoma

Cancers
Cancer ResearchOncology
2019English

Extended Dose Ipilimumab With a Peptide Vaccine: Immune Correlates Associated With Clinical Benefit in Patients With Resected High-Risk Stage IIIc/IV Melanoma

Clinical Cancer Research
Cancer ResearchOncology
2010English

P1.15-17 Risk Factors of Local Recurrence in EGFR-Mutant Stage III-pN2 Adenocarcinoma After Complete Resection: A Multi-Center Real-World Cohort Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

ASO Author Reflections: Frequent Relapses Prior to the Start of Adjuvant Therapy in Stage IIIB/C Melanoma

Annals of Surgical Oncology
OncologySurgery
2019English

NCI 8628: A Randomized Phase 2 Study of Ziv-Aflibercept and High-Dose Interleukin 2 or High-Dose Interleukin 2 Alone for Inoperable Stage III or IV Melanoma

Cancer
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy